Most recent by Erik Swain
Sotagliflozin effect on HbA1c, weight may vary by kidney function, dose
ORLANDO — In patients with type 2 diabetes, sotagliflozin improved HbA1c and body weight compared with placebo, though the treatment effect varied by kidney function, according to a meta-analysis.
Radiofrequency ablation viable treatment for papillary thyroid carcinoma
ORLANDO — For low-risk patients with papillary thyroid carcinoma interested in something other than surgery or surveillance, radiofrequency ablation may be an option, according to a speaker.
Agent improves skeletal dynamics, renal function at 2 years for hypoparathyroidism
ORLANDO — Among patients with chronic hypoparathyroidism, palopegteriparatide improved skeletal dynamics and renal function at 2 years, according to new data from the PaTHway trial.
Veligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye disease
ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the THRIVE and THRIVE-2 trials.
FDA Recap: April, May big months for intervention, electrophysiology approvals
Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available treatments to new patient populations.
Semaglutide linked to less risk for fractures vs. sleeve gastrectomy
ORLANDO — In a retrospective cohort study using propensity matching, among patients with obesity, those taking semaglutide had lower risk for fractures than those who underwent sleeve gastrectomy.
Thrombectomy system removes clots, improves quality of life for patients with PE
A novel thrombectomy system met its safety and efficacy goals and improved functional status and quality of life for patients with acute pulmonary embolism, according to results of the AVENTUS single-arm trial.
After decades of research, ‘we don’t fully know’ how GLP-1s work
ORLANDO — Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies so widely, Daniel J. Drucker, MD, said in a keynote speech.
GLP-1s tied to better survival after PCI for heart attack in patients with diabetes
Among patients with diabetes who underwent PCI after an acute heart attack, those taking a GLP-1 had better survival rates than those not taking one, researchers reported.
Crinecerfont enables reductions in androstenedione, improves reproductive hormones
ORLANDO — In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose and androstenedione level in children and improved reproductive hormone levels in adults, new data show.